Why the study?
Despite the promise of therapeutic angiogenesis to assist cardiac regeneration after myocardial infarction, clinical growth factor trials have lacked clinical translation with inconsistent results.
Despite promising concepts, therapeutic angiogenesis using growth factors for cardiac regeneration after MI has not successfully translated to clinical practice, highlighting the need for innovative approaches like combinatorial therapies.
Therapeutic angiogenesis with growth factors should not inform post-MI practice; leaves open isoform-specific and combinatorial strategies for future trials.
Ischaemic heart disease is the primary cause of death worldwide with myocardial infarction (MI) contributing to significant morbidity and mortality. The human heart has a limited capacity to regenerate and the significant loss of cardiomyocytes after MI can overwhelm this limited innate regenerative capability. This is in part compensated for by the creation of collagen-rich scar tissue. Therapeutic angiogenesis is an exciting prospect that can assist cardiac regeneration after MI with various approaches having been explored. This review will focus on results from clinical growth factor trials, and the lack of clinical translation. Inconsistencies in results from these may be due to heterogeneity within patient selection and an incomplete understanding of therapeutic differences between isoforms of active agents. The technology used has also evolved with recombinant protein and, subsequently, gene therapy being utilised. Innovative therapeutic designs, such as combinatorial therapies, might help to resolve these issues in the future.
No takes yet. Share an insight, caveat, or question.
Deshmukh et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: